

for new publications other than those increasingly influenced by the pharmaceutical industry, and above all, to create spaces for independent research and publications.

## REFERENCES

1. Perner MS. Transformaciones en el abordaje de la diabetes: análisis de las evidencias científicas publicadas por dos sociedades científicas (1980-2010). *Salud Colectiva*. 2013;9(3):373-389.
2. Sociedad Argentina de Diabetes. Convergencias, divergencias, variabilidad, puntos de corte e indicación de la glucemia de ayuno, la hemoglobina glucosilada e insulinemia [Internet]. Jornadas Rioplatenses; 24-25 abr 2010; Colonia, República Oriental del Uruguay [cited 21 Jan 2014]. Available from: [http://www.diabetes.org.ar/docs/jornadas\\_rioplatenses\\_trabajo\\_final.pdf](http://www.diabetes.org.ar/docs/jornadas_rioplatenses_trabajo_final.pdf).

3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2012;35(6):1364-1379.

4. Ministerio de Salud de la Nación. Ley 23753 [Internet]. 1989 [cited 21 Jan 2014]. Available from: <http://www.msal.gov.ar/ent/images/stories/insitucional/pdf/ley-nacional-de-diabetes-23753.pdf>.

5. Ministerio de Salud de la Nación. Ley 26914 [Internet]. 2013 [cited 21 Jan 2014]. Available from: <http://www.infoleg.gov.ar/infolegInternet/anexos/220000-224999/224327/norma.htm>.

## CITATION

Linari MA. Published evidence and transformations in the management of diabetes. *Salud Colectiva*. 2014;10(2):279-281.

## Response to “Published evidence and transformations in the management of diabetes”

### Respuesta a la carta “La evidencia publicada y las transformaciones en el abordaje de la diabetes”

**Perner, Mónica Serena**<sup>1</sup>

<sup>1</sup>Physician. Specialist in Epidemiology. Researcher and professor, Universidad Nacional del Comahue, Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina. [serenaperner@gmail.com](mailto:serenaperner@gmail.com)

Firstly, I would like to thank María Amelia Linari for her letter (1) as a member of the Executive Committee of the Argentine Diabetes Society (SAD) [*Sociedad Argentina de Diabetes*], one of the institutions referred to in the article of my authorship published in *Salud Colectiva* (2). This scientific association was selected as an indispensable actor in the construction of the knowledge required to manage such a complex issue as diabetes, given both its history and its

potential influence in health professionals involved in diabetes management. Therefore, I believe that it is of great priority to engage in conversations that can further the discussion.

In this sense, Emma Dominguez Alonso states:

Diabetes mellitus, particularly type 2, is a disease whose development and evolution are directly related to social factors. Unhealthy lifestyles, lack of indispensable knowledge for the prevention and adequate control of the disease, the inaccessibility of high-quality health care services, among others, favor the development of the disease and, at the same time, have a negative influence on the prognosis. The social origin of all of these conditioning factors classify diabetes mellitus, with ever increasing evidence, as a social disease. (3 p.305)

Different studies have analyzed the social determinants, showing, for instance, the impact that differences in body weight (as marker of the socioeconomic differences) have in the incidence of (4) and mortality due to type 2 diabetes (5).

Additionally, type 2 diabetes is not distributed equally among different social groups: it shows a larger incidence, greater complications and higher mortality rates in those with lower socioeconomic levels as well as among women and ethnic minorities (6). Possible explanations for this social pattern of diabetes have been given, such as the availability and accessibility of food and areas in which to carry out physical activity, differences in access to health care and health information, and healthy behaviors within the different socioeconomic groups (4).

Nancy Fleischer and Ana Diez Roux mention that "the information available since the beginning of the 1960s shows that a low socioeconomic level [...] is generally associated with greater morbidity and mortality due to heart disease in high-income countries" (7 p.642). There is an increasing amount of research showing the effect of social inequities in cardiovascular disease in high-income countries but, according to these authors' review (7), these types of studies are scarce in Latin America, where "in general, particularly with respect to obesity, diabetes and diet, health inequalities were more pronounced among women and in urban areas" (7 p.644).

In this respect, I agree with María Amelia Linari when she claims that it is "crucial to understand in depth the factors that can be beneficial or harmful to health" (1 p.279). Therefore, I believe we should deepen our knowledge regarding inequalities in health care. I also agree that we need to individualize treatment according to the "characteristics, conditions and history of each diabetes patient" (1 p.280). In order to deal comprehensively with such a complex issue as diabetes, it is important to gather information at the local level. We need to build strategies and interventions at the individual level but that are at the same time articulated with population level; that is, we must have an individualized approach with a focus on health inequalities, according to the profile of our population.

In the approach to diabetes (prevention, diagnosis and treatment), it is important to reconsider these concepts. Many innovations and therapeutic changes have been contributions of great value and practical application, with great impact on the quality of life of those with diabetes. However, innovations that approach

diabetes from a health inequalities perspective are few.

In Carlos Tajer's words, as long as the pharmaceutical industry remains "one of the most lucrative, with high profitability for shareholders," it will promote the incorporation of discoveries "within a context of growing health care costs." For this reason, "many clinical trials are conceptually oriented towards the positioning of the drug in the market rather than the specific interests of the patient or the community" (8 p.277).

According to Maarten Boers, cited by Antonio Ugalde and Nuria Homedes (8), "the enormous financial interests involved in the development of new drugs exert pressure on the scientific analysis and the presentation of the results obtained from the most important clinical trials" (9 p.311). In so doing, economic benefits take priority over the need to address health issues.

If research is funded by the pharmaceutical industry, the profit motive will come first. Consequently, the focus will be placed on treatment with drugs, the incorporation of new drugs and the initiation of pharmacologic treatment as early into the disease as possible, reducing the values considered normal to include more people as diabetic in early drug treatment.

---

## REFERENCES

1. Linari MA. La evidencia publicada y las transformaciones en el abordaje de la diabetes. *Salud Colectiva*. 2014;10(2):279-281.
2. Perner MS. Transformaciones en el abordaje de la diabetes: análisis de las evidencias científicas publicadas por dos sociedades científicas (1980-2010). *Salud Colectiva*. 2013;9(3):373-389.
3. Domínguez AE. Desigualdades sociales y diabetes mellitus. *Revista Cubana de Endocrinología* [Internet]. 2013 [cited 21 May 2014];24(2):200-213. Available from: <http://scielo.sld.cu/pdf/end/v24n2/end09213.pdf>.
4. Stringhini S, Tabak A, Akbaraly T, Sabia S, Shipley M, Marmot M, Brunner E, Batty D, Bovel P, Kivimäki M. Contribution of modifiable risk factors to social inequalities in type 2 diabetes: prospective Whitehall II cohort study. *British Medical Journal* [Internet]. 2012 [cited 21 May 2014];345:e5452. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424226/pdf/bmj.e5452.pdf>.
5. Franco M, Bilal U, Orduñez P, Benet M, Morejón A, Caballero B, Cooper R. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular

mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological comparison of secular trends. *British Medical Journal* [Internet]. 2013 [cited 21 May 2014];346:f1515. Available from: <http://www.bmj.com/content/346/bmj.f1515.pdf%2Bhtml>.

6. Ricci-Cabello I, Ruiz-Pérez I, Orly de Labry-Lima A, Marquez-Calderón S. Do social inequalities exist in terms of the prevention, diagnosis, treatment, control and monitoring of diabetes? A systematic review. *Health and Social Care in the Community* [Internet]. 2010 [cited 21 May 2014];18(6):572-587. Available from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2524.2010.00960.x/pdf>.


7. Fleischer N, Diez Roux AV. Inequidades en enfermedades cardiovasculares en Latinoamérica. *Revista Peruana de Medicina Experimental y Salud Pública* [Internet]. 2013 [cited 21 May 2014];30(4):641-648. Available from: <http://www.scielosp.org/pdf/rpmesp/v30n4/a17v30n4.pdf>.

8. Tajer C. Una era compleja en la interpretación de las evidencias científicas en cardiología. *Revista de la Federación Argentina de Cardiología* [Internet]. 2008 [cited 21 May 2014];37(4):276-282. Available from: [http://www.fac.org.ar/1/revista/08v37n4/art\\_opinion/opinion01/tajer.pdf](http://www.fac.org.ar/1/revista/08v37n4/art_opinion/opinion01/tajer.pdf).

9. Ugalde A, Homedes N. Medicamentos para lucrar: La transformación de la industria farmacéutica. *Salud Colectiva* [Internet]. 2009 [cited 21 May 2014];5(3):305-322. Available from: <http://www.unla.edu.ar/saludcolectiva/revista15/1.pdf>.

#### CITATION

Perner MS. Response to "Published evidence and transformations in the management of diabetes". *Salud Colectiva*. 2014;10(2):281-283



Content is licensed under a Creative Commons

Attribution — You must attribute the work in the manner specified by the author or licensor (but not in any way that suggests that they endorse you or your use of the work).

Noncommercial — You may not use this work for commercial purposes.

The translation of this article is part of an interdepartmental collaboration between the Undergraduate Program in Sworn Translation Studies (English < > Spanish) and the Institute of Collective Health at the Universidad Nacional de Lanús. This article was translated by Patricia De Souza Martínez and Pamela López, reviewed by María Pibernus and modified for publication by Vanessa Di Cecco.